Steffen Thistrup joined MVA’s Oncology Network Meeting
On the 24th of August, NDA Advisory Board Director, Steffen Thirstrup participated in the Medicon Valley Alliance (MVA) Oncology Network Meeting – Developing Orphan Drugs within Oncology
The was held as a 90-minute webinar and was hosted by Ascelia Pharma who shared knowledge on how they are building an international biotech company focusing on Orphan Oncology. Steffen represented NDA and provided expert insights into the Regulatory challenges in small populations and TFS HealthScience discussed patient recruitment and patient identification in orphan oncology.
Steffen’s presentation was given as part of a session focusing on orphan indications in oncology, but the fundamental regulatory challenges are the same independent of which orphan indication you are pursuing. Therefore, we believe that Steffen’s session provides insights to all drug developers within the orphan space, and not only for developers of orphan oncology drugs.
Watch the whole presentation in the video down below!
About Medicon Valley Alliance Oncology Network
MVA Oncology Network is a professional and social network within oncology initiated by prof. and entrepreneur Nils Brünner (University of Copenhagen) and prof. and entrepreneur Carl Borrebaeck, (Lund University).
The objective of the network is to strengthen collaboration, networking and knowledge-sharing within the region’s oncology ecosystem and bring together industry, academia and healthcare to stimulate commercialization and growth
The network focuses on best practices, experience and current challenges for public-private collaboration and the commercialization of oncology-related R&D in the Medicon Valley region.